Participants 36 64 4
chronic hepatitis B patients
Participants 227 319 4
chronic hepatitis B patients treated with different doses of recombinant hepatitis B vaccine
Participants 329 420 9
Seventy-two chronic hepatitis B patients who did not use any anti-HBV drugs within 6 months
Participants 516 617 3
The patients in different groups were treated with different doses of recombinant hepatitis B vaccine
Participants 699 741 3
All patients were followed up for 24 weeks
Participants 1151 1185 5
patients who were ELISPOT positive
Participants 1581 1650 3
n the placebo group, none of the patients showed undetectable HBV DNA
